Department of Biochemical, Physiological and Nutritional Sciences, Section of Physiology and Human Nutrition, University of Messina, Italy.
Nutr Metab Cardiovasc Dis. 2010 Jun;20(5):332-40. doi: 10.1016/j.numecd.2009.04.012. Epub 2009 Jul 23.
Recent evidence suggests that genistein aglycone may act beneficially on surrogate cardiovascular risk markers in postmenopausal women. We assessed the effects of genistein aglycone on some cardiovascular risk factors and homocysteine levels after 3-years of continued therapy in a cohort of osteopenic, postmenopausal women.
The parent study was a randomized, double-blind, placebo-controlled trial involving 389 postmenopausal women with low bone mass for 24 months. Subsequently, a subcohort (138 patients) continued therapy for an additional year. Participants received 54mg of genistein aglycone (n=71) or placebo (n=67), daily. Both arms received calcium and vitamin D(3) in therapeutic doses. Moreover, 4 weeks before randomization procedures and during our follow-up study, all patients received dietary instructions in an isocaloric fat-restricted diet. Blood lipid profiles, fasting glucose and insulin, insulin resistance (HOMA-IR), fibrinogen, osteoprotegerin (OPG) and homocysteine at baseline and after 24 and 36 months of treatment were measured. Compared to placebo, genistein significantly decreased fasting glucose and insulin, HOMA-IR, fibrinogen and homocysteine after 24 and 36 months of treatment. By contrast, isoflavone administration did not affect high-density lipoprotein cholesterol and triglycerides though serum OPG was higher in the genistein recipients. There were no differences in adverse events or discomfort between groups. Results on routine biochemical, liver function, and hematologic testing did not change over time in placebo or genistein group.
After 3-years of treatment, genistein aglycone plus calcium, vitamin D(3) and a healthy diet showed positive effects on some cardiovascular risk factors and homocysteine levels in a cohort of postmenopausal women with low bone mass.
最近的证据表明，染料木黄酮苷元可能对绝经后女性的替代心血管风险标志物有益。我们评估了染料木黄酮苷元在骨质疏松绝经后妇女队列中连续治疗 3 年后对一些心血管危险因素和同型半胱氨酸水平的影响。
该研究为一项随机、双盲、安慰剂对照试验，共纳入 389 名低骨量绝经后妇女，进行了 24 个月的治疗。随后，亚队列（138 例患者）继续治疗了额外的 1 年。参与者每日接受 54mg 染料木黄酮苷元（n=71）或安慰剂（n=67）治疗。两个治疗组均接受治疗剂量的钙和维生素 D(3)。此外，在随机分组前 4 周和我们的随访研究期间，所有患者均接受了低脂肪限制热量的饮食指导。在基线、治疗 24 个月和 36 个月时测量血脂谱、空腹血糖和胰岛素、胰岛素抵抗（HOMA-IR）、纤维蛋白原、骨保护素（OPG）和同型半胱氨酸。与安慰剂相比，染料木黄酮苷元治疗 24 个月和 36 个月后可显著降低空腹血糖和胰岛素、HOMA-IR、纤维蛋白原和同型半胱氨酸。相反，异黄酮的给予虽然增加了血清 OPG，但对高密度脂蛋白胆固醇和甘油三酯没有影响。两组之间在不良事件或不适方面没有差异。安慰剂或染料木黄酮苷元组的常规生化、肝功能和血液学检查结果在治疗期间未随时间发生变化。
经过 3 年的治疗，染料木黄酮苷元联合钙、维生素 D(3)和健康饮食对低骨量绝经后妇女的一些心血管危险因素和同型半胱氨酸水平产生了积极影响。
